Maternal exposure to prescription and non-prescription pharmaceuticals or drugs of abuse and risk of craniosynostosis

International Journal of Epidemiology

Volumn 27, Issue 1, 1998, Pages 64-67

  Gardner, Jacqueline S ^a   Guyard Boileau, Beatrice ^b   Alderman, Beth W ^a   Fernbach, Sandra K ^c   Greene, Carol ^d   Mangione, Ellen J ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d CHILDREN S HOSPITAL   (United States)

^e Colorado Department of Health ^*  (United States)

Author keywords

Craniosynostosis; Maternal exposure; Nitrosatable drugs; Pharmacoepidemiology

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; HYDANTOIN; METAL COMPLEX; NITROFURANTOIN; NON PRESCRIPTION DRUG; RETINOIC ACID; VALPROIC ACID;

ARTICLE; CHILD; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; DIET SUPPLEMENTATION; DRUG ABUSE; DRUG EXPOSURE; FETUS; HUMAN; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL PERIOD; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; REPERFUSION INJURY;

CASE-CONTROL STUDIES; COLORADO; CONFIDENCE INTERVALS; CRANIOSYNOSTOSES; DATA COLLECTION; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; NITROSO COMPOUNDS; ODDS RATIO; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; STREET DRUGS;

EID: 0031888582     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/27.1.64     Document Type: Article

References (30)

1. Becker LE, Hinton DR. Pathogenesis of craniosynostosis. Pediatr Neurosurg 1995;22:104-07.
2. Cohen MM Jr (ed.). Craniosynostosis: Diagnosis, Evaluation and Management. New York: Raven Press, 1986.
3. Vander Kolk CA, Beaty T. Etiopathogenesis of cranio-facial anomalies. Clinics in Plastic Surgery 1994;21:481-88.
4. Bradley CM, Alderman BW, Williams M A et al. Parental occupations as risk factors for craniosynostosis in offspring. Epidemiol 1995;6: 306-10.
5. Marion RW. Syndromes, genetics and the craniofacial complex. In: Goodrich J T, Hall C D. Craniofacial Anomalies: Growth and Development from a Surgical Perspective. New York: Thieme Medical Publishers, Inc., 1995.
6. Olshan AF, Faustman EM. Nitrosatable drug exposure during pregnancy and adverse pregnancy outcome. Int J Epidemiol 1989; 18: 891-99.
7. Shaw EB, Steinbach HL. Aminopterin-induced fetal malformation. Survival of an infant after attempted abortion. Am J Dis Child 1968; 115:477-82.
8. Milunsky A, Graef JW, Gaynor MF. Methotrexate-induced congenital malformations. J Pediatr 1968;72:790-95.
9. Burr W. Prescribing in pregnancy. Thyroid disease. Clin Obstet Gynaecol 1986;13:277-90.
10. Goodrich JT, Hall CD. Craniofacial Anomalies: Growth and Development from a Surgical Perspective. New York: Thieme Medical Publishers, Inc., 1995.
11. Beeram MR, Abedin M, Shoroye A et al. Occurrence of craniosynostosis in neonates exposed to cocaine and tobacco in utero. J Natl Med Assoc 1993;85:865-68.
12. Holm IA, Clarren SK. An unusual pattern of malformation associated with gestational exposure to nasal spray. J Pediatr 1985;106:860-61.
13. Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr Phila 1995;34:73-78.
14. Alderman BW, Fernbach SK, Bradley CM, Gegen NE, Barón AE, Mangione EJ. Increased risk of craniosynostosis with maternal cigarette smoking during pregnancy. Teratology 1994;50:13-18.
15. Alderman BW, Zamudio S, Barón AE et al. Increased risk of craniosynostosis with higher antenatal maternal altitude. Int J Epidemiol 1995;24:420-26.
16. Drug Facts and Comparisons. St Louis: Facts and Comparisons, Inc., 1995.
17. Alderman BW, Zamudio S, Mangione EJ. Maternal prenatal physical activity and risk of infant craniosynostosis. Presentation to XIV International Scientific Meeting, International Epidemiological Association, August 1996, Nagoya, Japan.
18. Friedman JJM, Polifka JE. Teratogenic Effects of Drugs. A Resource for Clinicians: TERIS. Baltimore: Johns Hopkins University Press, 1994.
19. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Wadsworth, Inc., 1982.
20. Brambilla G. Genotoxic effects of drug/nitrite interaction products: evidence for the need of risk assessment. Pharm Res Comm 1985;17: 307-21.
21. Brambilla G, Cajelli E, Finollo R, Maura A, Pino A, Robbiano L. Formation of DNA-damaging nitroso compounds by interaction of drugs with nitrite. A preliminary screening for detecting potentially hazardous drugs. J Toxic Environ Health 1985;15:1-24.
22. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, Inc., 1977.
23. Piper JM, Baum C, Kennedy DL, Price P. Maternal use of prescribed drugs associated with recognized fetal adverse drug reactions. Am J Obstet Gynecol 1988;159:1173-77.
24. Little BB, Gilstrap LC III. Drugs in Pregnancy. New York: Elsevier, 1992.
25. Fantel AG, Barber CV, Mackler B. Ischemia/reperfusion: a new hypothesis for the developmental toxicity of cocaine. Teratology 1992; 46:285-92.
26. Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Letters 1995;93:17-48.
27. Goode HF, Webster NR, Howdle P D et al. Reperfusion injury, antioxidants and hemodynamics during orthotopic liver transplantation. Hepatology 1994;19:354-59.
28. Bhaskar L, Mathan M M, Balasubramanian KA. Oxygen free radical-induced damage during colonie ischemia/reperfusion in rats. Mol Cell Biochem 1995;151:9-14.
29. Sooranna SR, Morris NH, Steer PJ. Placental nitric oxide metabolism. Reprod Fertil Dev 1995;7:1525-31.
30. Werler MM, Lammer EJ, Rosenberg L, Mitchell AA. Maternal Vitamin A Supplementation in relation to selected birth defects. Teratology 1990;42:497-503.